Skip to main content

What the FDA labels say about taking them together

Methylergonovine and rifampin

Methylergonovine's FDA label of May 1, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name methylergonovine. The methylergonovine label: “CYP3A4 inducers Drugs that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate.”

Check it at the source: the methylergonovine FDA label on DailyMed (effective May 1, 2026, Teva Pharmaceuticals USA, Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).

What does the methylergonovine label say about rifampin?

Methylergonovine label, drug interactions

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate.

Source: FDA drug label (Methylergonovine Maleate), Teva Pharmaceuticals USA, Inc., effective May 1, 2026 (SPL set d8e4b8ed-3289-4611-8a61-2392a4bf6072), via openFDA; the full label on DailyMed

What does the rifampin label say about methylergonovine?

Rifampin's label (effective February 11, 2026) does not name methylergonovine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Methylergonovine generic labelers
13Rifampin generic labelers
MethylergonovineRifampin
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)$4.50 per tablet 0.2 mg tablet$0.679 per capsule 300 mg capsule
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?